Loading...
Market
What will be the US Department of Veterans Affairs' response to hormone therapy safety concerns by mid-2025?
2
Resolution / Starting Odds
Policy change • 25%
Further research funded • 25%
No action • 25%
Other • 25%
Official statement or policy update from the US Department of Veterans Affairs
Story
Report Links Estrogen Hormone Therapy to Thyroid Cancer in Three Transgender Veterans
Oct 16, 2024, 04:10 PM
A recent report has linked hormone replacement therapy, specifically estrogen, to the development of thyroid cancer in three transgender military veterans. All three individuals, born male and identifying as female, underwent hormone therapy and subsequently were diagnosed with cancer. Medical professionals treating these patients noted that it is 'conceivable' that the hormone therapy could have contributed to their conditions, referencing previous research that associates estrogen with tumor growth. The report has prompted calls from doctors for further investigation into the safety of hormone treatments for transgender individuals.
View original story
Similar markets
Yes • 50%
No • 50%
Provision remains unchanged • 25%
Provision is amended • 25%
Provision is removed • 25%
Provision is overturned by court • 25%
Majority support the provision • 25%
Majority oppose the provision • 25%
Evenly divided opinion • 25%
Unclear or no significant opinion • 25%
Issue warning • 25%
Update guidelines • 25%
No changes • 25%
Other • 25%
Federal Legislation Passed • 25%
Executive Action Taken • 25%
Legal Challenges Initiated • 25%
No Significant Action • 25%
Provision remains unchanged • 25%
Provision is modified • 25%
Provision is removed • 25%
Other outcome • 25%
Yes • 50%
No • 50%
Widespread protests • 25%
Legal challenges • 25%
Minimal public response • 25%
Supportive public demonstrations • 25%
Implement new regulations • 25%
Conduct further research • 25%
No action taken • 25%
Other • 25%
Full relief granted • 25%
Partial relief granted • 25%
No relief granted • 25%
Ongoing investigation • 25%
No Action Taken • 25%
Publication Mandated • 25%
Funding Reallocation • 25%
Other Outcome • 25%